Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

first 48 weeks of treatment. For example, in CAPACITY 2 and CAPACITY 1 the Week 48 rank ANCOVA p values were 0.001 and 0.005; the relative reductions in LS means from the repeated measures analysis were 46% and 29%, respectively. The difference between the CAPACITY 2 and CAPACITY 1 primary endpoint results at Week 72 may have been due to a modest attenuation in the rate of FVC decline in the placebo group subsequent to Week 48 in CAPACITY 1.

Secondary Endpoint Results

In CAPACITY 2, pirfenidone treatment was associated with a statistically significant effect on the pre-specified secondary endpoints of PFS (p = 0.023) and Categorical Change in FVC (p = 0.001) when compared to placebo. A PFS event was defined in the study protocol as the time to death, a 10% decrease in FVC or a 15% decrease in DL(CO). In CAPACITY 1, pirfenidone treatment was associated with a statistically significant effect in the pre-specified secondary endpoint of Six-Minute Walk Test distance (p = 0.001) when compared to placebo. There were no other statistically significant findings on any of the other pre-specified secondary endpoints in either study and pirfenidone treatment was not associated with a worse outcome on any endpoints.

Although pooled analyses of secondary endpoints were pre-specified in the study protocol, these analyses are nonetheless considered exploratory because the primary endpoint of both studies was not met. Analyses of pooled data for the pre-specified secondary endpoints of both CAPACITY studies showed a treatment effect favoring pirfenidone on three: PFS (p = 0.029); Categorical FVC Change (p = 0.003) and Six-Minute Walk Test distance (p = 0.004). While the studies were not powered to demonstrate an effect on overall survival, the pooled hazard ratio (pirfenidone: placebo) was 0.78 (p= 0.326).

Safety and Tolerability Results

Safety data from both studies show that pirfenidone wa
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) today ... Officer, is scheduled to present at the BIO ... on Wednesday, October 10. The presentation is ... accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ,657575 and ...
... 3 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... its clinical development and discovery programs at,two upcoming investor conferences: ... Presentation: Monday, October 8, 2007 at 8:00 a.m. Eastern ... the Carlton Hotel on Madison Avenue in New York ...
... With more than 70 million,Generation Y employees starting ... global workplace, smart companies are paying,attention, providing these ... their wants and needs. (Photo: http://www.newscom.com/cgi-bin/prnh/20071003/AQW903 ... is the global health care company,Abbott, which was ...
Cached Biology Technology:Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 2Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 3Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 4
(Date:9/29/2014)... research team says recently identified radiation detection properties of ... doors for homeland security and medical advances. , In ... issue of Optics Letters , UT Arlington Physics ... method to fabricate transparent nanoscintillators by heating nanoparticles composed ... is formed. A scintillator refers to a material ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... URBANA, Ill. University of Illinois scientists have found ... they,ve found them in a pretty unlikely placethe crushed ... used in jet fuel. , "The bioactive compounds in ... of Pleasure, are a mixture of phytochemicals that ... The seed meal is a promising nutritional supplement because ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2
... GA--As water use and runoff regulations become more stringent ... an issue, finding ways to increase the efficiency of ... study contains answers that can help horticultural growers address ... the research study, explained that most often horticultural best ...
... In co-operation with a research group from Singapore, scientists ... molecules in the form of truncated O-glycans aid growth ... able to decode the significance of these truncated O-glycans, ... the journal PNAS , represent an important contribution ...
... recognised diabetes expert. He heads the Institute for Diabetes ... is the scientific director of the Helmholtz Diabetes Center ... Chair of Metabolic Diseases at the Technische Universitt Mnchen ... of the control of fat and sugar metabolism, with ...
Cached Biology News:Sensors allow for efficient irrigation, give growers more control over plant growth 2Specific sugar molecule causes growth of cancer cells 2
...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Contains L-glutamine...
... Protein (PEBP) does not share significant ... PEBP is expressed in the ... muscle, and stomach. One important ... exerting inhibitory activity against several serine ...
Biology Products: